IMU Biosciences, a London, UK-based techbio company working in the field of the immune powered precision medicine, raised £11.5M in Series A funding.
The round was led by Molten Ventures.
The company intends to use the funds to accelerate its roadmap, including its novel CytAtlas® platform, foster new strategic partnerships and projects, conduct immune research, and expand its operations into the Boston/Cambridge, MA, area.
Led by Dr Adam Laing, IMU Biosciences is combining deep, systems-level immune profiling with a proprietary AI platform to build a detailed immune atlas spanning the breadth of human health and disease. Its CytAtlas® platform is working on the immune system to empower research and clinical practice, from diagnostics to drug development and treatment response, and with application across multiple high-growth areas, including immune-oncology, cell therapy, autoimmune disorders and transplantation.
In conjunction with the fundraising, Tim Haines was appointed to the IMU Biosciences Board of Directors as Non-executive Chair and Dr Oliver Nussbaumer, Ph.D. and Inga Deakin, D. Phil. were appointed as Non-executive Directors.
Commenting on the news, Adam Laing said: “This systems-level approach to understanding immune function enables us to look at the bigger picture rather than just focusing on individual disease-associated parameters. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run.”
FinSMEs
24/01/2024